论文部分内容阅读
目的探讨术中区域性缓释化疗在中晚期食管癌综合治疗的临床效果,为中晚期食管癌患者的临床治疗提供有效的治疗方案。方法选取2011年1月至2016年6月间在江苏省中医院治疗的中晚期食管癌患者90例,随机分为实验组和对照组,每组45例。两组均采用食管癌根治术治疗,实验组在手术中局部植入混合化疗药物进行间质治疗,对照组仅进行单纯的手术治疗。两组患者在术后均进行常规化疗,且化疗方案相同。比较两组患者术后并发症、化疗不良反应、复发及生存情况。结果实验组和对照组患者术后并发症发生率及术后1、2年生存率比较差异无统计学意义(P>0.05)。对照组术后2年肿瘤复发率(44.44%)明显高于实验组(22.22%),差异有统计学意义(P<0.05)。实验组患者术后3年生存率为80.00%,明显高于对照组的42.22%,两组比较差异有统计学意义(P<0.05)。结论术中区域性缓释化疗在中晚期食管癌综合治疗中能降低肿瘤的复发率,且不会引起术后并发症的发生。
Objective To investigate the clinical effect of intraoperative regional slow-release chemotherapy in the treatment of advanced esophageal cancer and provide an effective treatment for the clinical treatment of advanced esophageal cancer patients. Methods 90 patients with advanced esophageal cancer who were treated in Jiangsu Provincial Hospital of Traditional Chinese Medicine from January 2011 to June 2016 were randomly divided into experimental group and control group with 45 cases in each group. Both groups were treated with radical resection of esophageal cancer. The experimental group was implanted with mixed chemotherapeutic drugs locally for interstitial surgery in the operation group, while the control group was treated only by simple operation. Both groups underwent routine chemotherapy after the operation, and the chemotherapy regimens were the same. Postoperative complications, adverse reactions, recurrence and survival of the two groups were compared. Results The incidence of postoperative complications and the postoperative 1 and 2 year survival rates in experimental group and control group were not significantly different (P> 0.05). The tumor recurrence rate (44.44%) in the control group 2 years after operation was significantly higher than that in the experimental group (22.22%) (P <0.05). The 3-year survival rate of the experimental group was 80.00%, which was significantly higher than that of the control group (42.22%). There was significant difference between the two groups (P <0.05). Conclusion Intraoperative regional slow-release chemotherapy in the treatment of advanced esophageal cancer can reduce the recurrence rate of tumor, and will not cause postoperative complications.